<div id="readability-page-1"><p><span>Arcellx (NASDAQ:ACLX - Get Free Report)</span>'s stock had its &#34;buy&#34; rating restated by equities researchers at Canaccord Genuity Group in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $130.00 target price on the stock. Canaccord Genuity Group's price target points to a potential upside of 70.27% from the company's current price.</p><p>ACLX has been the topic of several other research reports. Wolfe Research assumed coverage on Arcellx in a research note on Tuesday, November 18th. They issued a &#34;peer perform&#34; rating on the stock. Citigroup  reaffirmed a &#34;buy&#34; rating on shares of Arcellx in a research report on Monday, November 24th. Needham &amp; Company LLC  reaffirmed a &#34;buy&#34; rating and issued a $105.00 price objective on shares of Arcellx in a research note on Monday. Guggenheim  reissued a &#34;buy&#34; rating on shares of Arcellx in a research note on Monday, November 24th. Finally, Stifel Nicolaus  set a $129.00 price target on shares of Arcellx and gave the stock a &#34;buy&#34; rating in a report on Thursday, October 16th. Eight equities research analysts have rated the stock with a Buy rating, two have issued  a Hold rating and one  has issued  a Sell rating to the stock. Based on data from MarketBeat, Arcellx  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $115.50.</p><p><b>View Our Latest Analysis on ACLX</b></p><h2>Arcellx Price Performance</h2><p>Shares of Arcellx stock traded up $6.79 during midday trading on Monday, hitting $76.35. 2,230,192 shares of the company were exchanged, compared to its average volume of 672,067. The firm has a 50 day simple moving average of $83.90 and a 200-day simple moving average of $74.54. Arcellx has a 52 week low of $47.86 and a 52 week high of $94.07. The firm has a market cap of $4.41 billion, a P/E ratio of -19.57 and a beta of 0.34. </p><p>Arcellx (NASDAQ:ACLX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.03). Arcellx had a negative net margin of 607.01% and a negative return on equity of 51.13%. The business had revenue of $4.95 million during the quarter, compared to the consensus estimate of $11.24 million.  Equities research analysts expect that  Arcellx will post -1.58 earnings per share for the current year. </p><h2>Insiders Place Their Bets</h2><p>In other Arcellx news, insider Christopher Heery sold 21,034 shares of the firm's stock in a transaction dated Tuesday, September 30th. The stock was sold at an average price of $81.28, for a total value of $1,709,643.52. Following the completion of the transaction, the insider owned 624 shares in the company, valued at $50,718.72. This trade represents a 97.12% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 37,486 shares of company stock worth $3,030,736 in the last three months. 8.35% of the stock is owned by company insiders. </p><h2>Institutional Trading of Arcellx</h2><p>Several hedge funds and other institutional investors have recently bought and sold shares of ACLX. Vanguard Group Inc. lifted its holdings in  Arcellx by 19.7% in the 1st quarter. Vanguard Group Inc. now owns 3,985,156 shares of the company's stock worth $261,426,000 after buying an additional 655,064 shares during the period.  Covestor Ltd boosted its stake in  Arcellx by 47.6% in the 1st quarter. Covestor Ltd now owns 2,137 shares of the company's stock worth $140,000 after purchasing an additional 689 shares in the last quarter.  Invesco Ltd. grew its holdings in shares of  Arcellx by 13.9% during the first quarter. Invesco Ltd. now owns 30,242 shares of the company's stock valued at $1,984,000 after buying an additional 3,692 shares during the last quarter.  Nuveen LLC bought a new stake in shares of  Arcellx in the 1st quarter worth $7,333,000.  Finally, Knott David M Jr bought a new stake in  Arcellx in the 1st quarter worth about $984,000. Hedge funds and other institutional investors own  96.03% of the company's stock. </p><h2>Arcellx Company Profile</h2> (Get Free Report)<p>Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).</p><h2>See Also</h2><ul><li>Five stocks we like better than Arcellx</li><li>What is a SEC Filing?</li><li>D-Wave's 22% Surge: What's Behind the December Rally?</li><li>5 discounted opportunities for dividend growth investors</li><li>Netflix Wins the Streaming Wars: The $82B Warner Bros. Deal</li><li>Top Biotech Stocks: Exploring Innovation Opportunities</li><li>5 Robotics Stocks Catching Momentum After New Policy Tailwinds</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arcellx Right Now?</h2><p>Before you consider Arcellx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.</p><p>While Arcellx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ACLX

<p>Canaccord Genuity Group reiterated a "buy" rating for Arcellx (NASDAQ:ACLX) with a $130 price target, indicating a potential 70.27% upside. Eight analysts rate the stock as Buy, with a consensus rating of "Moderate Buy" and an average target price of $115.50. Arcellx's stock traded at $76.35, with a market cap of $4.41 billion. Insiders sold shares worth $3,030,736 recently, and institutional investors own 96.03% of the stock.</p>

Arcellx (NASDAQ:ACLX) Given Buy Rating at Canaccord Genuity Group